Overview
The marketing authorisation for Eperzan has been withdrawn at the request of the marketing-authorisation holder.
Eperzan : EPAR - Summary for the public
English (EN) (562.4 KB - PDF)
български (BG) (624.69 KB - PDF)
español (ES) (542.87 KB - PDF)
čeština (CS) (607.9 KB - PDF)
dansk (DA) (541.22 KB - PDF)
Deutsch (DE) (544.32 KB - PDF)
eesti keel (ET) (540.43 KB - PDF)
ελληνικά (EL) (630.45 KB - PDF)
français (FR) (547.85 KB - PDF)
hrvatski (HR) (562.04 KB - PDF)
italiano (IT) (540.11 KB - PDF)
latviešu valoda (LV) (622.24 KB - PDF)
lietuvių kalba (LT) (565.35 KB - PDF)
magyar (HU) (595.19 KB - PDF)
Malti (MT) (608.19 KB - PDF)
Nederlands (NL) (541.07 KB - PDF)
polski (PL) (605.32 KB - PDF)
português (PT) (542.53 KB - PDF)
română (RO) (565.97 KB - PDF)
slovenčina (SK) (606.51 KB - PDF)
slovenščina (SL) (598.09 KB - PDF)
Suomi (FI) (540.84 KB - PDF)
svenska (SV) (540.92 KB - PDF)
Product information
Eperzan : EPAR - Product Information
English (EN) (1.3 MB - PDF)
български (BG) (3.78 MB - PDF)
español (ES) (1.31 MB - PDF)
čeština (CS) (2.61 MB - PDF)
dansk (DA) (1.28 MB - PDF)
Deutsch (DE) (2.91 MB - PDF)
eesti keel (ET) (1.28 MB - PDF)
ελληνικά (EL) (3.79 MB - PDF)
français (FR) (1.85 MB - PDF)
hrvatski (HR) (2.06 MB - PDF)
italiano (IT) (2.35 MB - PDF)
lietuvių kalba (LT) (2.5 MB - PDF)
magyar (HU) (2.8 MB - PDF)
Malti (MT) (3.61 MB - PDF)
Nederlands (NL) (1.74 MB - PDF)
norsk (NO) (1.9 MB - PDF)
polski (PL) (3.46 MB - PDF)
português (PT) (2.22 MB - PDF)
română (RO) (1.49 MB - PDF)
slovenčina (SK) (2.84 MB - PDF)
slovenščina (SL) (2.84 MB - PDF)
Suomi (FI) (1.7 MB - PDF)
svenska (SV) (1.9 MB - PDF)
Latest procedure affecting product information: II/0031
14/09/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Eperzan : EPAR - All Authorised presentations
English (EN) (464.95 KB - PDF)
български (BG) (530.35 KB - PDF)
español (ES) (464.99 KB - PDF)
čeština (CS) (512.08 KB - PDF)
dansk (DA) (461.05 KB - PDF)
Deutsch (DE) (479.46 KB - PDF)
eesti keel (ET) (473.97 KB - PDF)
ελληνικά (EL) (515.98 KB - PDF)
français (FR) (465.85 KB - PDF)
hrvatski (HR) (480.51 KB - PDF)
íslenska (IS) (545.36 KB - PDF)
italiano (IT) (556.13 KB - PDF)
latviešu valoda (LV) (511.54 KB - PDF)
lietuvių kalba (LT) (508.44 KB - PDF)
magyar (HU) (504.72 KB - PDF)
Malti (MT) (511.91 KB - PDF)
Nederlands (NL) (475.83 KB - PDF)
norsk (NO) (476.21 KB - PDF)
polski (PL) (522.9 KB - PDF)
português (PT) (473.83 KB - PDF)
română (RO) (511.84 KB - PDF)
slovenčina (SK) (511.2 KB - PDF)
slovenščina (SL) (496.05 KB - PDF)
Suomi (FI) (470.96 KB - PDF)
svenska (SV) (473.85 KB - PDF)
Product details
- Name of medicine
- Eperzan
- Active substance
- Albiglutide
- International non-proprietary name (INN) or common name
- albiglutide
- Therapeutic area (MeSH)
- Diabetes Mellitus, Type 2
- Anatomical therapeutic chemical (ATC) code
- A10BJ04
Pharmacotherapeutic group
Drugs used in diabetesTherapeutic indication
Eperzan is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycaemic control as:
Monotherapy
When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to contraindications or intolerance.
Add-on combination therapy
In combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see section 4.4 and 5.1 for available data on different combinations).
Authorisation details
- EMA product number
- EMEA/H/C/002735
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
D24 YK11
Ireland - Opinion adopted
- 22/01/2014
- Marketing authorisation issued
- 20/03/2014
- Revision
- 8
Assessment history
Eperzan : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (656.63 KB - PDF)
Eperzan : EPAR - Public assessment report
English (EN) (4 MB - PDF)
CHMP summary of positive opinion for Eperzan
English (EN) (523.8 KB - PDF)
News on Eperzan
More information on Eperzan
Public statement on Eperzan: Withdrawal of the marketing authorisation in the European Union
English (EN) (104.26 KB - PDF)